Compare Ginkgo Bioworks Holdings Inc (DNA) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs KKR & Co Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.91 (market cap $763.64M), while KKR & Co Inc trades at $91.11 (market cap $80.39B). The key difference: KKR & Co Inc is far larger — about 105.3× Ginkgo Bioworks Holdings Inc's market cap, and KKR & Co Inc pays a 0.87% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and KKR & Co Inc for 67 Days on average.
| DNA | KKR | |
|---|---|---|
Market Cap | $763.64M | $80.39B |
Volume | 3,204,177 | 6,517,705 |
Sector | Health | Financials |
52-Week High | $15.83 | $142.75 |
52-Week Low | $5.48 | $83.88 |
Typical Hold Time | 7 Days | 67 Days |
Enterprise Value | $865.59M | $2.95B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
KKR trades at $92.48, up 3.13% today, showing strong momentum after recent earnings beats. The stock faces bearish technical signals but maintains solid fundamentals with $19.21B revenue and $2.37B net income for 2025. Recent business developments include strategic joint ventures and asset sales, while analyst consensus remains overwhelmingly bullish with an average price target of $123.30.
KKR presents a compelling investment opportunity with strong earnings momentum and institutional support, though technical indicators suggest near-term caution. The company's diversified investment portfolio and active deal flow provide growth catalysts, balanced by market volatility risks and the cyclical nature of private equity returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
